UK markets open in 1 hour 25 minutes
  • NIKKEI 225

    27,811.11
    +263.11 (+0.96%)
     
  • HANG SENG

    26,425.37
    -896.61 (-3.28%)
     
  • CRUDE OIL

    71.56
    -0.51 (-0.71%)
     
  • GOLD FUTURES

    1,807.30
    +5.50 (+0.31%)
     
  • DOW

    35,061.55
    +238.15 (+0.68%)
     
  • BTC-GBP

    27,899.37
    +2,853.86 (+11.39%)
     
  • CMC Crypto 200

    919.36
    +125.63 (+15.83%)
     
  • ^IXIC

    14,836.99
    +152.39 (+1.04%)
     
  • ^FTAS

    4,025.12
    +33.64 (+0.84%)
     

Marinomed Biotech AG expands distribution of Corona virus blocker Carragelose into Brazil and Mexico

·5-min read

DGAP-News: Marinomed Biotech AG / Key word(s): Alliance
06.07.2021 / 07:45
The issuer is solely responsible for the content of this announcement.

Marinomed Biotech AG expands distribution of Corona virus blocker Carragelose into Brazil and Mexico

Korneuburg, Austria, 06 July 2021 - Marinomed Biotech AG (VSE:MARI), an Austrian science-based biotech company with globally marketed therapeutics derived from innovative proprietary technology platforms, announced today that Carragelose based nasal sprays have been outlicensed for the Brazilian and Mexican markets. Marinomed has entered into an exclusive license agreement with M8 Pharmaceuticals (formerly moksha8). M8 is a specialty pharmaceutical company focused on licensing, marketing, and distributing innovative and established therapeutics in the two largest Latin American markets, Brazil and Mexico. M8 will be responsible for pursuing the local approvals in Brazil and Mexico, after which the Carragelose nasal spray will be launched under the trade name Barlo(R), further expanding the geographical reach. Carragelose products are already available without prescription (OTC) in more than 40 countries. Carragelose has a clinically proven high efficacy in preventing infection and viral spread of multiple respiratory viruses including both endemic Corona viruses such as OC43 as well as SARS-CoV-2.

"An agreement with a partner as experienced and strong on the Latin American markets like M8 underlines Marinomed's increasing recognition and helps us to expand the global reach of Carragelose," said Dr. Andreas Grassauer, CEO of Marinomed. "We strongly believe that the antiviral efficacy of Carragelose, inactivating SARS-CoV-2 independently of the actual variant, can make an important contribution in combating the pandemic, supporting the preventative hygiene measures taken worldwide."

Carragelose has been well established to prevent respiratory infections by various viruses, including certain influenza and endemic Coronaviruses.1 Since the beginning of the COVID-19 pandemic, Carragelose has been shown to effectively inactivate both wildtype2 and common variants3 of the new Coronavirus SARS-CoV-2, including the so-called P1 or gamma variant. Clinical data from an independent study in Argentina had demonstrated an 80 % reduction in PCR-confirmed COVID-19 cases in hospital staff after Carragelose-treatment.4

About Carragelose(R):
Carragelose(R) is a sulfated polymer from red seaweed and is a unique, broadly active anti-viral compound. It is known as a gentle yet effective and safe prevention and treatment against various viral respiratory infections. Several clinical and preclinical studies have shown that Carragelose(R) forms a layer on the mucosa which wraps entering viruses, thereby inactivates them and prevents them from infecting cells. Increasing clinical evidence indicates that Carragelose(R) can also inactivate SARS-CoV-2.1,4 Marinomed is the holder of the IP rights and has licensed Carragelose(R) for marketing in Europe, parts of Asia, Canada, and Australia. For a full list of Marinomed's portfolio of Carragelose(R) containing nasal sprays and oral products, please visit https://www.carragelose.com/en/portfolio/launched-products, for a list of scientific publications on Carragelose(R), please visit https://www.carragelose.com/en/publications.

About Marinomed Biotech AG
Marinomed Biotech AG (Korneuburg, Austria) (VSE:MARI) is an Austrian science-based biotech company with globally marketed therapeutics listed on the Prime Market of the Vienna Stock Exchange. The company focuses on the development of innovative products based on two patent-protected technology platforms. The Marinosolv(R) technology platform increases the efficacy of hardly soluble compounds for the treatment of sensitive tissues such as eyes, nose, lung or gastrointestinal tract. The Carragelose(R) platform comprises innovative patent-protected products targeting viral infections of the respiratory tract and can reduce the risk of an infection with SARS-CoV-2. Carragelose(R) is used in nasal sprays, throat sprays and lozenges, which are sold via international partners in over 40 countries worldwide. Marinomed, Marinosolv(R) and Carragelose(R) are registered trademarks of Marinomed AG. These trademarks may be owned or licensed in select locations only. Further information is available at https://www.marinomed.com/en/technologies-markets/markets.

1 https://www.carragelose.com/en
2 https://www.marinomed.com/en/news/marinomed-biotech-ag-publishes-new-supporting-data-on-the-in-vitro-efficacy-of-carragelose-against-sars-cov-2
3 https://www.marinomed.com/en/news/marinomed-biotech-ag-announces-positive-data-demonstrating-carragelose-efficacy-against-sars-cov-2-variants
4 https://www.marinomed.com/en/news/marinomed-biotech-ag-shares-positive-clinical-trial-results-for-iota-carrageenan-nasal-spray-in-the-prevention-of-covid-19-1

For further inquiries contact:

Marinomed Biotech AG                                   
Lucia Mayr-Harting
Hovengasse 25, 2100 Korneuburg, Austria
T +43 2262 90300
E-mail: pr@marinomed.com
http://www.marinomed.com

International Media and IR Contact
MC Services AG
Dr. Brigitte Keller, Julia Hofmann
T +49 89 210228 0
UK: Shaun Brown
M: +44 7867 515 918
E-mail: marinomed@mc-services.eu

 

Disclaimer
This press release contains forward-looking statements, which are based on current views, expectations and projections of the management of Marinomed Biotech AG about future events. These forward-looking statements are subject to risks, uncertainties and assumptions that could cause actual results, performance or events to differ materially from those described in, or expressed or implied by, such statements. The current views, expectations and projections of the management of Marinomed Biotech AG may be identified by the context of such statements or words such as "anticipate," "believe", "estimate", "expect", "intend", "plan", "project" and "target". Forward-looking statements are only valid as of the date they are made and Marinomed Biotech AG does not assume any obligation to update, review or revise any forward-looking statements contained in this press release whether as a result of new information, future developments or otherwise.


06.07.2021 Dissemination of a Corporate News, transmitted by DGAP - a service of EQS Group AG.
The issuer is solely responsible for the content of this announcement.

The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.
Archive at www.dgap.de

show this
show this
Our goal is to create a safe and engaging place for users to connect over interests and passions. In order to improve our community experience, we are temporarily suspending article commenting